Feature | August 29, 2012| Dave Fornell

Bioresorbable Vascular Closure Devices Speed Ambulation

 An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure dev

An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure device, showing the attached PEG plug that had expanded into the tissue tract.

Vascular closure devices that use an active method to immediately seal the femoral access site can enable faster patient ambulation, reduce nursing time and speed discharge. However, one of the biggest issues interventionalists have with active vascular closure devices is the use of a permanent piece of hardware to stitch or clip the arteriotomy closed. Three companies now offer fully bioresorbable, active vascular closure devices, including a recent release earlier this year.  

In February 2012, the U.S. Food and Drug Administration (FDA) cleared AccessClosure’s new MynxGrip Vascular Closure Device (VCD). Built on the Mynx platform, the MynxGrip VCD adds the company’s patented Grip Technology sealant to the distal end of the original Mynx sealant, resulting in a better seal on the vessel and filling the tissue tract.

Hemostasis is achieved through the delivery of a water-soluble, bio-inert, non-thrombogenic polyethylene glycol (PEG) polymer on the shaft of a delivery catheter to the surface of the artery. The new formulation of PEG adheres better to the contours of the vessel wall. The material swells in size to fill the tissue tract. The sealant fully resorbs within 30 days. A 6 mm semi-compliant balloon is inflated against the arterial wall to establish temporary hemostasis during deployment of the sealant and ensures its extra-arterial placement. The result is an active seal that leaves no foreign material behind inside the vessel. 

Cordis Corp. gained FDA clearance for the Exoseal vascular closure device in May 2011. It incorporates an extravascular, bioabsorbable polyglycolic acid (PGA) plug. It is designed to close the femoral artery puncture site with minimal or no inflammation, is fully reabsorbed in 60-90 days. 

St. Jude Medical’s Angio-Seal line also offers a bioabsorbable active closure system. It includes use of an intra-arterial anchor attached to a suture and a collagen seal.

Related Content

Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures, SCAI, Corindus CorPath 200
News | Robotic Systems| May 16, 2017
The largest real-world study of robotic percutaneous coronary intervention (PCI) demonstrated clinical and technical...
Adept Medical Launches IR Platform, interventional radiology
Technology | Cath Lab| May 16, 2017
Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and...
Race, Gender and Socioeconomic Factors Impact PCI Outcomes, PLATINUM Diversity study, SCAI 2017
News | Cath Lab| May 15, 2017
A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Day of the Week PCI-Related Hospitalization Occurs Determines Likelihood of Survival, SCAI 2017
News | Cath Lab| May 15, 2017
In a large-scale analysis of percutaneous coronary intervention (PCI)-related hospitalizations, people admitted to the...
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init